
Fennec Pharmaceuticals Inc.: financial statements
Price
$13.33
November 18, 2026Market cap $460M
What Ploutos Investor adds for Fennec Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 23% since Nov 12, 2026, when the 10-Q these figures come from was filed ($10.90 then, $13.39 on Nov 18, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+44.9% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $21M | $48M | $45M | +44.9% |
| Cost of revenue | $1.3M | – | – | |
| Gross profit | $20M | – | – | |
| Operating income | -$13M | $2.6M | -$6.3M | |
| Net income | -$16M | -$436.0K | -$9.7M | |
| Earnings per share | -$0.60 | -$0.02 | -$0.34 | |
| Earnings per share, basic | -$0.60 | -$0.02 | -$0.34 | |
| Margins | ||||
| Gross margin | 94.1% | – | – | |
| Operating margin | -60.1% | 5.4% | -14.1% | |
| Net margin | -75.5% | -0.9% | -21.8% | |
Financial statements
FENC's revenue, profits and cash flows from 2011 to 2022, 11 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
When the debt falls due
Dec 31, 2024Due within 2 years
$0
Principal of loans and bonds falling due, from the annual report dated December 31, 2024, without leases and interest. The filing
- 2025: –
- 2026: –
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
15.0%
Effective rate
-1.1%
The company paid -1.1% in tax on its profit, 16.1 points below the statutory rate it starts from (15.0%). Below, the reasons it gives.
The lines the company states do not reach its effective rate, so we do not show them. Both rates are the filing's. The filing
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Taxes: deferred and paid
The deferred part was 0.0% of the tax charge in the year to Dec 31, 2025. The rows show the last 2 years.
Cash taxes paid were 705.7% of the current tax charge in the year to Dec 31, 2025.
- Deferred share, year to Dec 31, 2025$0 of $106.0K
- 0.0%
- Deferred share, year to Dec 31, 2024$0 of $365.0K
- 0.0%
- $748.0K paid, $106.0K current
- 705.7%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
The earnings per share split is not shown: it needs a profit before tax in both years, since a tax rate on a loss has no meaning as a source.
Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Fennec Pharmaceuticals's filings show?
These are Fennec Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did FENC have in 2025?
Fennec Pharmaceuticals had revenue of $45M and net income of -$9.7M in fiscal 2025, a net margin of -21.8%.
How much debt does FENC have?
On December 31, 2025 Fennec Pharmaceuticals had total assets of $71M, debt of – and shareholders' equity of $35M.
Where are the figures from?
From Fennec Pharmaceuticals Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.